undamentalytics Newsletter
Sign in

Immunitybio, Inc. income statement

In fiscal 2025, Immunitybio, Inc. reported revenue of $113m, up 668.3% on the year before, operating income of −$256m (a -226.0% margin) and net income of −$351m, or −$0.38 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1100002110115113166
Cost of revenue—————————00011
Gross profit—————————0115113165
Research and development0211294256112140196248232190——
Selling, general and administrative252289557434671135103130169——
Operating income—−6−239−125−99−98−156−221−330−351−362−344−256−252
Interest expense00001—69156412911561—
Income before tax—−6−237−121−97−97−160−226−350−417−584−414−352−993
Income tax00−0−1−0−1−0−200−00−0−0
Net income−2−6−237−121−96−96−158−222−347−417−583−414−351−992
Diluted EPS−$0.26−$0.75−$3.31−$1.47−$1.20−$1.22−$0.43−$0.59−$0.89−$1.04−$1.15−$0.62−$0.38−$0.99
Diluted shares (average)8m8m72m82m81m79m366m377m389m400m509m700m920m1,004m
EBITDA—−6−237−121−94−89−142−208−316−333−344−327−241−236

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IBRX vs NUVBBEAM vs IBRXABUS vs IBRXIBRX vs KPTI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immunitybio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immunitybio, Inc.